IGF-1 LR3 (Long R3) - Meditech - 100mcg × 10 vials
Buy IGF-1 LR3 1mg in India — Meditech Research Grade
IGF-1 LR3 - Extended IGF-1 Receptor Agonist
→ Compare all 2 IGF-1 LR3 brands in IndiaSynthetic 83-amino-acid IGF-1 analogue with N-terminal extension and Arg³ substitution. ~3× more potent than native IGF-1 with a 20–30 hour half-life. Strict research-only chemical.
Order this product
Factory-sealed box: 100mcg × 10 vials. Ready for immediate dispatch.
🚚 Pan-India delivery / Cash on Delivery available
Why researchers reach for IGF-1 LR3
~3× IGF-1 potency
Reduced IGF-binding-protein affinity keeps more peptide circulating freely - the basis for its enhanced potency relative to native IGF-1.
Long half-life (20–30 hrs)
Once-daily dosing achievable - vs. native IGF-1's minute-scale half-life that requires constant infusion.
Hypertrophy + hyperplasia
Animal-model research shows IGF-1 LR3 drives both fibre growth (hypertrophy) and new fibre formation (hyperplasia) - distinct from most anabolic agents.
PI3K/Akt/mTOR activation
Hits the central anabolic signalling cascade - the same pathway behind insulin's metabolic effects and most growth-factor-driven hypertrophy.
Community Insights
Self-reported by pep-pedia.org users and published research summaries. Not clinical evidence.
How IGF-1 LR3 Works
Reduced IGFBP binding
The N-terminal extension and R3 substitution disrupt binding to IGF-binding proteins, keeping LR3 free in plasma rather than sequestered.
Full IGF-1 receptor agonism
Binds and activates the IGF-1 receptor identically to native IGF-1, but at higher effective concentrations because the free fraction is higher.
PI3K/Akt/mTOR + MAPK/ERK
Activates both the metabolic (PI3K/Akt/mTOR - protein synthesis, glucose uptake) and proliferative (MAPK/ERK) IGF-1 signalling cascades.
Mechanism summary sourced from pep-pedia.org and the published peptide research literature.
Stack It With
Pairs Well
CJC-1295 with DAC
Adds long-acting GHRH-driven endogenous GH/IGF-1 to direct IGF-1 receptor signalling - covers both upstream and downstream of the GH/IGF-1 axis.
Pairs Well
MGF
Pairs systemic IGF-1 receptor signalling with local satellite-cell activation - complementary mechanisms behind muscle hypertrophy research.
Full Specifications
Frequently Asked Questions
Why is hypoglycemia a major risk?
IGF-1 LR3 activates PI3K/Akt - the same insulin signalling cascade. With high free fraction and long half-life, it drives strong glucose uptake into cells, lowering blood sugar. Pep-pedia's safety guidance: consume 30–60g fast carbohydrates immediately post-injection and never inject before sleep (overnight hypoglycemia risk).
Cancer concerns?
IGF-1 receptor activation drives cellular proliferation broadly - not just in muscle. Pep-pedia explicitly states IGF-1 LR3 is contraindicated for any cancer history or undiagnosed growths. Animal models show prolonged use can drive organ hypertrophy (heart, intestines).
WADA prohibited?
Yes. IGF-1 LR3 is on the WADA prohibited list and will cause failed drug tests in athletes. Use is strictly research-only.
How long can a cycle run?
Pep-pedia caps research cycles at 4–6 weeks maximum. Longer use carries cumulative organ hypertrophy and cancer-proliferation concerns. Brief, well-bracketed cycles are the published norm.
Storage requirements?
Strict cold chain. Lyophilized at −20°C to −80°C; reconstituted vials at 2–8°C. Freeze-thaw cycles degrade IGF-1 LR3 - keep one working vial refrigerated and the rest in deep freeze.
Ready to order
IGF-1 LR3 - Meditech
₹9,200 · 100mcg × 10 vials · Lyophilized powder + BAC water · Pan-India delivery
Add to CartResearch Use Only
This product is intended solely for laboratory and research purposes. It is not intended for human consumption, therapeutic use, or as a food or drug product. By purchasing, you confirm that this product will be used exclusively for legitimate research applications.